Illimis Therapeutics

Illimis Therapeutics is a pioneering biotechnology company at the forefront of developing innovative therapies for challenging central nervous system (CNS) and immune-related diseases. The company's core strength lies in its proprietary GAIA (Gas6-mediated Anti-inflammatory Adaptor Protein) platform. This cutting-edge platform is designed to harness the therapeutic potential of TAM (Tyro3, Axl, Mer) receptor biology, a key pathway involved in regulating inflammation and immune responses.